


Eurofins CALIXAR Revenue
Biotechnology Research • Lyon, Auvergne-Rhône-Alpes, France • 11-20 Employees
Eurofins CALIXAR revenue & valuation
| Annual revenue | $1,500,000 |
| Revenue per employee | $116,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $4,800,000 |
| Total funding | $1,100,000 |
Key Contacts at Eurofins CALIXAR
Rodolphe Simonot
Ceo / President
Geoffrey Donsimoni
Marketing Director, Europe
Kerstin Kanonenberg
Scientific Director
Company overview
| Headquarters | 60 AVENUE ROCKEFELLER, LYON, 69008, FR |
| Phone number | +33481076460 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Extraction, Chemistry, Isolation, Crystallization, Transporter, Purification, Stabilization, Target Validation, Expression, Structure Based Drug Design, Gpcr, Therapeutic Antibodies, Ion Channel, Membrane Protein, Native Receptors, Therapeutic Targets, Vaccine Discovery |
| Founded | 2011 |
| Employees | 11-20 |
| Socials |
Eurofins CALIXAR Email Formats
Eurofins CALIXAR uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@clinisciences.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@clinisciences.com | 100% |
About Eurofins CALIXAR
To contact us : contact@calixar.com CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens. We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays. As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial. Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages. By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.). For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions. CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Eurofins CALIXAR has 7 employees across 4 departments.
Departments
Number of employees
Eurofins CALIXAR Tech Stack
Discover the technologies and tools that power Eurofins CALIXAR's digital infrastructure, from frameworks to analytics platforms.
Security
Analytics
Cookie compliance
CDN
JavaScript libraries
Miscellaneous
Security
Advertising
Page builders
Analytics
Payment processors
Frequently asked questions
4.8
40,000 users



